Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MPL | P40238 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.37 |
| ▸ | RELA | Q04206 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474416 | 0.86 | ALDH1A1 (0.48) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL27898751 | 0.84 | ALDH1A1 (0.42) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL16995488 | 0.84 | RAB9A (0.54) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL473573 | 0.83 | TRPA1 (0.43) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL475099 | 0.81 | RAB9A (0.50) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL10171329 | 0.80 | RAB9A (0.49) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL1801918 | 0.79 | ALDH1A1 (0.66) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL474243 | 0.79 | MPL (0.52) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL474265 | 0.77 | FFAR4 (0.46) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL474173 | 0.77 | MPL (0.47) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411395-B1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| EP-2411395-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109329-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | ALDH1A1 449/4885RAB9A 2462/4885NPC1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.